CN109310654A - 包含含硫化合物的微粒 - Google Patents

包含含硫化合物的微粒 Download PDF

Info

Publication number
CN109310654A
CN109310654A CN201780035360.7A CN201780035360A CN109310654A CN 109310654 A CN109310654 A CN 109310654A CN 201780035360 A CN201780035360 A CN 201780035360A CN 109310654 A CN109310654 A CN 109310654A
Authority
CN
China
Prior art keywords
composition
particle
microns
thio
stabilizer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780035360.7A
Other languages
English (en)
Chinese (zh)
Inventor
D·奥尼尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NovaBiotics Ltd
Original Assignee
NovaBiotics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NovaBiotics Ltd filed Critical NovaBiotics Ltd
Publication of CN109310654A publication Critical patent/CN109310654A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pigments, Carbon Blacks, Or Wood Stains (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Accessories For Mixers (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780035360.7A 2016-06-07 2017-06-06 包含含硫化合物的微粒 Pending CN109310654A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662346969P 2016-06-07 2016-06-07
GB1609940.0 2016-06-07
US62/346,969 2016-06-07
GBGB1609940.0A GB201609940D0 (en) 2016-06-07 2016-06-07 Microparticles
PCT/GB2017/051637 WO2017212249A1 (en) 2016-06-07 2017-06-06 Microparticles comprising a sulphur-containing compound

Publications (1)

Publication Number Publication Date
CN109310654A true CN109310654A (zh) 2019-02-05

Family

ID=56508202

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780035360.7A Pending CN109310654A (zh) 2016-06-07 2017-06-06 包含含硫化合物的微粒

Country Status (16)

Country Link
US (1) US11369568B2 (enExample)
EP (1) EP3463325B1 (enExample)
JP (1) JP7195934B2 (enExample)
KR (1) KR102412212B1 (enExample)
CN (1) CN109310654A (enExample)
AU (1) AU2017277897B2 (enExample)
BR (1) BR112018075221B1 (enExample)
CA (2) CA3096121C (enExample)
DK (1) DK3463325T3 (enExample)
ES (1) ES2965017T3 (enExample)
FI (1) FI3463325T3 (enExample)
GB (1) GB201609940D0 (enExample)
MX (1) MX2018014278A (enExample)
SG (1) SG11201810934TA (enExample)
WO (1) WO2017212249A1 (enExample)
ZA (1) ZA201807852B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10905660B2 (en) 2016-06-07 2021-02-02 Novabiotics Limited Microparticles
EP3572068A1 (en) * 2018-05-22 2019-11-27 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. New salt of cysteamine for the preparation of highly respirable particles
PL3866775T3 (pl) * 2018-10-17 2025-07-07 Novabiotics Limited Cysteamina do zastosowania w leczeniu chorób płuc
JP2023540985A (ja) * 2020-09-03 2023-09-27 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム 噴霧乾燥低吸湿性活性粉末組成物
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
WO2023107996A1 (en) * 2021-12-07 2023-06-15 Cila Therapeutic Inc. Anti-viral therapeutic agents and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013538A1 (en) * 1989-05-02 1990-11-15 Aktiebolaget Draco Organic salts of cysteine derivatives
CN101342155A (zh) * 2007-07-11 2009-01-14 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
CN102341105A (zh) * 2009-02-03 2012-02-01 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
US20120135969A1 (en) * 2008-11-27 2012-05-31 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
WO2013120086A1 (en) * 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
CN105101955A (zh) * 2013-04-10 2015-11-25 纪元技术有限责任公司 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1830810A4 (en) * 2004-12-30 2011-02-02 Dobeel Co Ltd SPRAY-DRYED COMPOSITION WITH PROTEINS OF THE COLLECTIN FAMILY OR VARIATIONS THEREOF AND METHOD OF PREPARATION THEREOF
AR057623A1 (es) 2005-11-28 2007-12-05 Omega Bio Pharma H K Ltd Materiales y metodos para el tratamiento de las infecciones virales
WO2008077712A1 (en) 2006-12-22 2008-07-03 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Gel useful for the delivery of ophthalmic drugs
WO2010138419A2 (en) * 2009-05-23 2010-12-02 Obio Pharmaceutical (H.K.) Ltd. Materials and methods for treating viral infections
GB201021186D0 (en) * 2010-12-14 2011-01-26 Novabiotics Ltd Composition
AU2012254999B2 (en) 2011-05-19 2016-02-11 Savara, Inc. Dry powder vancomycin compositions and associated methods
JP5981123B2 (ja) * 2011-10-11 2016-08-31 サンサ コーポレーション （バルバドス） インク ニコチン薬の製造法およびその方法により製造される医薬
IN2014DN03049A (enExample) * 2011-10-26 2015-05-15 Seattle Childrens Res Inst
JP6483714B2 (ja) * 2013-10-11 2019-03-13 ローレンス エス． ジスマン， 噴霧乾燥製剤
GB201416716D0 (en) * 2014-09-22 2014-11-05 Novabiotics Ltd Use
ITUA20161799A1 (it) * 2016-03-18 2017-09-18 Recordati Ind Chimica E Farmaceutica S P A Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale
US10905660B2 (en) * 2016-06-07 2021-02-02 Novabiotics Limited Microparticles

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990013538A1 (en) * 1989-05-02 1990-11-15 Aktiebolaget Draco Organic salts of cysteine derivatives
CN101342155A (zh) * 2007-07-11 2009-01-14 天津帝士力投资控股集团有限公司 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法
US20120135969A1 (en) * 2008-11-27 2012-05-31 Boehringer Ingelheim International Gmbh Novel powdered crystalline medicines for inhalation
CN102341105A (zh) * 2009-02-03 2012-02-01 微生物公司 用作上皮组织、急性和慢性伤口、细菌生物被膜和其他适应症的抗菌剂的铋硫醇
WO2013120086A1 (en) * 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer
CN105101955A (zh) * 2013-04-10 2015-11-25 纪元技术有限责任公司 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BARBARA ELIZABETH BUCHAN: "FORMULATION STUDIES ON CYSTEAMINE FOR THE TREATMENT OF NEPHROPATHIC CYSTINOSIS", 《 HTTPS://RGU-REPOSITORY.WORKTRIBE.COM/OUTPUT/248165》 *
CEDRIC CHARRIER ET AL.: "Cysteamine (Lynovex®), a novel mucoactive antimicrobial & antibiofilm agent for the treatment of cystic fibrosis", 《ORPHANET JOURNAL OF RARE DISEASES》 *

Also Published As

Publication number Publication date
JP7195934B2 (ja) 2022-12-26
RU2018142841A3 (enExample) 2020-09-30
GB201609940D0 (en) 2016-07-20
KR102412212B1 (ko) 2022-06-23
RU2018142841A (ru) 2020-06-04
DK3463325T3 (da) 2024-01-02
CA3096121A1 (en) 2017-12-14
EP3463325B1 (en) 2023-11-08
NZ748596A (en) 2025-06-27
MX2018014278A (es) 2019-03-14
US20190175501A1 (en) 2019-06-13
BR112018075221A2 (pt) 2019-03-19
FI3463325T3 (fi) 2023-12-19
CA3026743A1 (en) 2017-12-14
EP3463325A1 (en) 2019-04-10
ES2965017T3 (es) 2024-04-10
WO2017212249A1 (en) 2017-12-14
AU2017277897B2 (en) 2022-09-08
CA3096121C (en) 2022-11-15
CA3026743C (en) 2024-05-28
ZA201807852B (en) 2023-05-31
SG11201810934TA (en) 2019-01-30
JP2019517541A (ja) 2019-06-24
AU2017277897A1 (en) 2018-12-20
KR20190016957A (ko) 2019-02-19
BR112018075221B1 (pt) 2024-02-06
US11369568B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
CN109310654A (zh) 包含含硫化合物的微粒
US10905660B2 (en) Microparticles
CN108434126B (zh) 治疗肺病的干粉配方与方法
EP2611438B1 (en) Dry powder formulations and methods for treating pulmonary diseases
JP6186458B2 (ja) 吸入用の一価金属カチオン乾燥粉末
ES2379775T3 (es) Formulaciones farmacéuticas y métodos para tratar infecciones del aparato respiratorio
US20130149345A1 (en) Respirably dry powder comprising calcium lactate, sodium chloride and leucine
RU2016140347A (ru) Аэрозольные фторхинолоны и их применения
Manniello et al. Clarithromycin and N-acetylcysteine co-spray-dried powders for pulmonary drug delivery: A focus on drug solubility
JP2012522009A (ja) 肺炎および人工呼吸器関連気管気管支炎を治療および予防するための方法
JP2012522012A (ja) 粘膜内層の生物物理学的性質の改変のためのクエン酸カルシウムおよび乳酸カルシウム製剤
Chan Inhalation drug delivery devices and emerging technologies
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
IL263540B2 (en) Microparticles that include a sulfur-containing compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination